B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Raf 265

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Raf 265, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

motesanib
34 shared targets
pazopanib
51 shared targets
cediranib
42 shared targets
brivanib
28 shared targets
doramapimod
41 shared targets
vandetanib
46 shared targets
nilotinib
34 shared targets
quizartinib
34 shared targets
defosbarasertib
33 shared targets
saracatinib
29 shared targets
Loading evidence profile...

This evidence profile for Raf 265 is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.